Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults ≥18 to ≤80 years of age~* History of T2DM for at least 6 months prior to screening~* Moderate to severe renal impairment and not actively on dialysis~* Willing and able to perform self-monitoring of blood glucose~* Willing and able to provide written informed consent~Exclusion Criteria:~* History of type 1 diabetes mellitus, diabetic ketoacidosis (within the previous 6 months), or diabetes resulting from pancreatic disorder or secondary diabetes (from acromegaly and/or Cushing's disease)~* Subjects who have received a renal allograft~* Subjects expecting to require dialysis or to undergo kidney transplantation within 3 months of study dosing~* Presence of active hepatic disease or clinically significant abnormal liver function tests at Screening or planned study Day -1~* Subjects with a history of heart attack, severe/unstable angina, or coronary revascularization procedure within 6 months prior to study Day -2~* History of clinically significant cardiac arrhythmias within 1 year prior to study Day -2~* Subjects with congestive heart failure~* Subjects with uncontrolled Stage III hypertension~* History of 2 or more emergency room visits, doctors' visits, or hospitalizations due to hypoglycemia within the 6 months prior to planned study Day -2~* History of alcohol or illicit drug abuse within 1 year prior to Screening~* History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C~* Major surgery within 6 months prior to planned study Day -2~* History of any malignancy within the last 5 years~* Triglycerides \>1000 mg/dL at Screening or planned study Day -1~* History of any serious adverse reaction or hypersensitivity to an SGLT inhibitor~* Use of corticosteroids within 2 weeks prior to study Day 1~* Use of any investigational drug within 30 days prior to study Day 1, or investigational protein or antibodies within 60 days of Day 1~* Positive urine pregnancy test at Screening~* Positive urine screen for illicit drug abuse at Screening~* Prior exposure to LX4211

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Treatment A (Type: EXPERIMENTAL): None
- LX4211 Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).